NEC Orchestrating Future Fund Invests in Aetion to Advance Real World Data and Evidence in Drug Development
Tokyo, February 19, 2025 –
In a significant move to bolster advancements in healthcare and drug development, NEC Orchestrating Future Fund, a cornerstone corporate venture capital fund, has made an investment in Aetion Inc., a leading U.S.-based provider of healthcare technology solutions. This strategic investment aims to strengthen the use of Real World Data (RWD) and Real World Evidence (RWE) in the pharmaceutical industry, paving the way for more effective and efficient drug development processes.
Navigating the Challenges of Real World Data and Evidence
The healthcare sector has seen a surge in the demand for RWD and RWE to assess drug efficacy and safety, streamline the drug development pipeline, and accelerate regulatory approvals. However, several hurdles must be addressed, including data collection, ensuring data quality standards, applying consistent analytical methods, and adhering to regulatory guidelines.
Aetion’s Global Leadership in Real World Evidence Platforms
Aetion is recognized globally as a pioneer in RWE platforms, providing a robust solution with the Aetion Evidence Platform® (AEP). Deployed by numerous stakeholders, including pharmaceutical firms, regulatory bodies, insurance companies, and healthcare institutions, AEP standardizes data quality and guarantees transparency. It facilitates rapid, precise analysis of varied data sources and transforms them into reliable RWE, thereby overcoming challenges associated with RWD/RWE utilization.
NEC’s Vision for Healthcare and Life Sciences
NEC’s healthcare and life sciences business is dedicated to addressing critical medical challenges and generating new value. Encompassing a wide array of services, including electronic medical records, NEC is committed to innovative solutions that enhance patient care and healthcare efficiency. Aetion’s proven track record in evaluating pharmaceutical efficacy and safety complements NEC’s expertise, offering synergies that promise to revolutionize the drug development process and pioneer new therapeutic methods.
The Partnership Perspective
“NEC Orchestrating Future Fund focuses on startups pioneering new markets with cutting-edge technologies and innovative business models,” stated Shigeki Wada, Corporate Senior Vice President of NEC Corporation. “Aetion’s RWD/RWE-based medical decision support is aligned with our vision of fostering personalized medicine and contributing to next-generation healthcare. Collaborating with Aetion, we will continues our mission of creating social value.”
“At Aetion, we are redefining how healthcare institutions make crucial decisions using enterprise-grade technology,” emphasized Jeremy Rassen, ScD, Chief Executive Officer and Co-founder of Aetion. “This partnership with NEC Orchestrating Future Fund highlights our commitment to empowering decision-makers with advanced solutions that promote measurable change globally.”
Impact on the Future of Healthcare
This investment marks a pivotal step towards harnessing the full potential of RWD and RWE in the pharmaceutical industry. By leveraging Aetion’s platform and NEC’s healthcare expertise, the partnership is poised to improve drug development efficiency, drive innovation, and shape the future of personalized medicine.
Conclusion
This strategic collaboration between NEC Orchestrating Future Fund and Aetion exemplifies the power of innovative investments and partnerships in driving progress in healthcare. By embracing cutting-edge technologies and focusing on patient-centric solutions, the future of medicine is set to become more effective, efficient, and personalized.
We invite you to share your thoughts on this groundbreaking development in healthcare innovation. Join the conversation by leaving a comment below, subscribing to our newsletter for future updates, or sharing this article on your social media platforms. Your engagement is valuable to us.
